cff | mecfa

MECFA Blog

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct lytic...

CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in...

New Combination of CFTR Mutations Found in Chinese Siblings With CF

A combination of two mutations, including one that had never been reported, were found in two Chinese siblings who developed a severe...

4DMT Receives Up to $14M from CFF for Development of Customized Gene Carrier

After being given more than $3 million from the Cystic Fibrosis Foundation (CFF) in 2017 to expand the development of viral vectors for...

Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows

Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to...

AzurRx BioPharma Will Conduct Phase 2b Trial of MS1819 at TDN Clinical Sites

AzurRx BioPharma has been authorized to conduct its Phase 2b OPTION 2 clinical trial evaluating MS1819, its investigative therapy for...

International Study Reports COVID-19 Outcomes in People With Cystic Fibrosis

Today the Cystic Fibrosis Foundation announced data from a collaborative, international effort to understand the impact of COVID-19 on...

CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says

Amplifiers, a potential new class of therapies that modify CFTR — the protein whose defects cause cystic fibrosis (CF) — do so by...

UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December

The National Institute for Health and Care Excellence (NICE) in the U.K. is currently in the process of evaluating Vertex...

Synspira Therapeutics, CF Foundation Agree to Support Development of SNSP003 for Malabsorption Syndr

The Cystic Fibrosis Foundation has reached an agreement with Synspira Therapeutics to support the further development of SNSP003, an...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p